

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

CHANGE IN SHAREHOLDING

This is a voluntary announcement made by the Company.

Further to the Transfers, the Company was informed by GS Corp that on 1 December 2017, each of Dr. Zhang and Ms. Wang transferred additional 50 million shares and 25 million shares of GS Corp to the Zhang Trust and the Wang Trust, respectively. As at 1 December 2017, GS Corp directly held 890,902,024 Shares, representing approximately 51.46% of the entire issued share capital of the Company.

Immediately after the Additional Transfers, each of Dr. Zhang, the Zhang Trust (through its trustee), Ms. Wang and the Wang Trust (through its trustee) are deemed, or taken to be interested in, all the Shares held by GS Corp.

The Board considers that the Additional Transfers will not have any impact on the financial position and operations of the Company and its subsidiaries.

Reference is made to the announcement of the Company dated 17 October 2017 (the “**Announcement**”) in relation to, among other things, the Transfers. Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the Announcement.

THE ADDITIONAL TRANSFERS

Further to the Transfers, the Company was informed by GS Corp that on 1 December 2017, each of Dr. Zhang and Ms. Wang transferred additional 50 million shares and 25 million shares of GS Corp to their respective family trusts, respectively. As at 1 December 2017, GS Corp directly held 890,902,024 Shares, representing approximately 51.46% of the entire issued share capital of the Company.

Immediately before the Additional Transfers, each of Dr. Zhang, the Zhang Trust (through its trustee), Ms. Wang and the Wang Trust (through its trustee) held approximately 39.96%, 1.09%, 11.45% and 0.55% of the entire issued share capital of GS Corp, respectively, and was deemed, or taken to be interested in, all the Shares held by GS Corp for the purpose of the Securities and Futures Ordinance.


Immediately after the Additional Transfers, each of Dr. Zhang, the Zhang Trust (through its trustee), Ms. Wang and the Wang Trust (through its trustee) held approximately 29.05%, 12.00%, 6.00% and 6.00% of the entire issued share capital of GS Corp, respectively, and was deemed, or taken to be interested in, all the Shares held by GS Corp for the purpose of the Securities and Futures Ordinance.

REASONS FOR THE ADDITIONAL TRANSFERS


The Additional Transfers are for their respective family wealth and succession planning purposes of Dr. Zhang and Ms. Wang.

SHAREHOLDING STRUCTURE

Immediately before the Additional Transfers



Immediately after the Additional Transfers



IMPLICATIONS

Immediately after the Additional Transfers, each of the Zhang Trust (through its trustee) and the Wang Trust (through its trustee) is deemed, or taken to be interested in, all the Shares held by GS Corp.

The Board considers that the Additional Transfers will not have any impact on the financial position and operations of the Company and its subsidiaries.

DEFINITIONS

“Additional Transfers”	the Zhang Additional Transfer and the Wang Additional Transfer;
“Board”	the board of directors of the Company;
“Company”	Genscript Biotech Corporation (金斯瑞生物科技股份有限公司*), an exempted company incorporated under the laws of the Cayman Islands with limited liability on 21 May 2015, whose shares are listed on the main board of the Stock Exchange (Stock Code: 1548);
“Dr. Zhang”	Dr. Zhang Fangliang, an executive Director of the Company;
“Ms. Wang”	Ms. Wang Ye, an executive Director of the Company;
“Shares”	ordinary shares of par value US\$0.001 each in the share capital of the Company;
“Stock Exchange”	the Stock Exchange of Hong Kong Limited;
“Transfers”	the Zhang Transfer and the Wang Transfer;
“Wang Additional Transfer”	the transfer of the aggregate 25 million shares of GS Corp by Ms. Wang to the Wang Trust for an aggregate price of US\$39,250,000 (which may be adjusted within 60 days to reflect the appraised value of the 25 million shares as determined by an independent appraiser), collectively representing approximately 5.45% of the entire issued share capital of GS Corp;

“Wang Transfer”	the transfer of the aggregate 2.5 million shares of GS Corp by Ms. Wang to the Wang Trust at nil consideration, collectively representing approximately 0.55% of the entire issued share capital of GS Corp;
“Wang Trust”	an irrevocable discretionary trust established by Ms. Wang on 5 October 2017 for the benefit of her spouse, her son and his living issue;
“Zhang Additional Transfer”	the transfer of the aggregate 50 million shares of GS Corp by Dr. Zhang to the Zhang Trust for an aggregate price of US\$78,500,000 (which may be adjusted within 60 days to reflect the appraised value of the 50 million shares as determined by an independent appraiser), collectively representing approximately 10.91% of the entire issued share capital of GS Corp;
“Zhang Transfer”	the transfer of the aggregate 5 million shares of GS Corp by Dr. Zhang to the Zhang Trust at nil consideration, collectively representing approximately 1.09% of the entire issued share capital of GS Corp; and
“Zhang Trust”	an irrevocable discretionary trust established by Dr. Zhang on 12 October 2017 for the benefit of his three children and their respective living issue.

By order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 4 December 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*